Garfall, Alfred L., et al. "Chimeric antigen receptor T cells against CD19 for multiple myeloma." New England Journal of Medicine 373.11 (2015): 1040-1047.
A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemotherapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-cell transplantation. Four years earlier, autologous transplantation with a higher melphalan dose (200 mg per square meter) had induced only a partial, transient response.
Leggi tutto l'articolo sul sito https://www.nejm.org/doi/10.